Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)

This randomised, controlled clinical trial (n=128) aims to investigate whether a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with alcohol use disorder (AUD).

Led by the University of Calgary and collaborating with Johns Hopkins University, University of Maryland, and the Canadian Institutes of Health Research (CIHR), this study targets male and female patients aged 22-65 with a moderate to severe AUD diagnosis. Participants will be randomly assigned to either a high dose (25mg) or a low dose (1mg) psilocybin arm. All participants will undergo 5 sessions of MET, starting 24 hours post-dosing.

The primary outcome measure will be the reduction in heavy drinking assessed by the Time Line Follow Back (TLFB) at 1-, 4-, and 12-weeks post-dosing. Secondary measures include abstinence, biomarkers of alcohol consumption, alcohol cue reactivity, cognitive flexibility, depression, anxiety, quality of life, glutamate and GABA levels, and resting-state functional connectivity.

Eligible participants must meet DSM-5 AUD criteria of at least moderate severity, have had at least 5 heavy drinking days in the past 30 days, and desire to decrease alcohol consumption. Exclusion criteria include severe or moderate substance use disorder other than alcohol or nicotine in the past 6 months, certain psychiatric diagnoses, active suicidal ideation, pregnancy, and notable abnormalities in medical tests.

Recruitment is not yet underway, with an estimated study start date of January 2024 and completion date of May 2027. The study will take place at the University of Calgary in Alberta, Canada.

Topic Alcohol Use Disorder Addiction
Compound Psilocybin
Country Canada
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 January 2024
End date 31 May 2027
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 128
Sex All
Age 22- 65
Therapy Yes

Trial Details

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

NCT Number NCT05995769

Sponsors & Collaborators

University of Calgary
The University of Calgary, located in Alberta, Canada, is a comprehensive academic and research institution.

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.